Full-Time

Senior Scientist 2

Downstream Development, Scale-Up Laboratory Lead

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$109.5k - $208.5k/yr

San Bruno, CA, USA

In Person

Bachelor's, Master's, PhD

Category
Biology & Biotech (1)

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • Degree in Chemical Engineering, Biochemistry, Chemistry, or other relevant scientific discipline with BS and typically 12+ years of experience, MS and typically 10+ years of experience, or PhD and typically 4+ years of experience
  • Significant experience in downstream/purification process development within a biologics CMC environment
  • Demonstrated expertise in process scale-up, scale-down model execution, and technology transfer
  • Must be an AKTA systems expert, including deep hands-on experience with UNICORN software
  • Hands-on experience operating large-scale TFF processes (hundreds of grams; e.g., Allegro, Cytiva, Repligen, or manually operated skids), packing 3–20 L columns with affinity and polishing resins, using single-use technologies (e.g., SUMs, pre-packed columns, AKTA flow kits, TFF flow kits), operating large-scale filtration processes including depth filtration, virus filtration, and chromatography membrane filtration, and executing large-volume formulations
  • Experience with large column packing, buffer preparation, equipment troubleshooting, and day-to-day laboratory execution
  • Proven ability to troubleshoot equipment issues and work effectively with vendors on repairs, reliability improvements, and technical feedback
  • Demonstrated leadership skills with ability to lead projects, influence decisions, and mentor others
  • Working knowledge of analytical methods such as HPLC, CE, UV-based quantitation, and impurity characterization used to support downstream development
  • Must work effectively in a team-based, highly collaborative, matrixed environment
  • Strong written and verbal communication skills, including technical writing and scientific data presentation
  • Ability to independently design, execute, and interpret experiments to solve complex technical problems
  • Strong understanding of biochemistry and bioprocess engineering principles relevant to downstream development and scale-up
  • Strong attention to detail and documentation practices
Responsibilities
  • Lead downstream scale-up lab activities and non-GMP material generation to support CMC development, optimization, and transfer of purification processes for biologic candidates across development stages
  • Maintain operational readiness of the scale-up lab, including equipment availability, workflow planning, consumables, and efficient activity scheduling
  • Serve as a subject matter expert and technical lead for downstream scale-up and technology transfer; collaborate with and provide technical guidance to project purification development representatives to support transfer to the scale-up lab and GMP manufacturing
  • Lead downstream technology transfer activities to internal manufacturing sites and external partners, including transfer package preparation, batch support, and resolution of scale-up or execution issues
  • Serve as an AKTA subject matter expert (AKTA Ready, AKTA Ready LX, AKTA Avant, AKTA Pure), including method development and execution using UNICORN software
  • Drive scientific understanding and execution of downstream unit operations, including resin- and membrane-based chromatography, filtration, viral clearance operations, high-concentration UF/DF, and formulation
  • Provide hands-on leadership in large column packing (AxiChrom, QuickScale, BPG), buffer preparation, equipment setup, and unit operation execution
  • Develop and implement scale-up lab operational workflows, procedures and documentation to enable efficient, reliable, and compliant execution of downstream development activities
  • Design and execute scale-down and scale-up studies to build process understanding, assess robustness, and improve manufacturing readiness
  • Troubleshoot process and equipment issues efficiently; work closely with vendors to resolve problems and provide feedback to improve systems and workflows.
  • Identify and implement next-generation purification platform strategies and workflow improvements to enhance scalability, robustness, efficiency, and cost effectiveness
  • Partner effectively across a matrixed organization with upstream, analytical, drug product, manufacturing, and engineering teams
  • Mentor junior scientists and, where applicable, manage direct reports through strong planning, communication, and scientific judgment
  • Author and review technical reports, development summaries, transfer documentation, and regulatory support documents
  • Work efficiently and collaboratively to meet program milestones while maintaining high standards for safety, documentation, and data integrity
  • Promote a strong safety culture by ensuring scale-up lab activities, equipment use, and material handling practices are executed in accordance with site safety and compliance requirements
Desired Qualifications
  • Experience leading or overseeing a downstream scale-up laboratory or comparable technical development function
  • Hands-on experience supporting transfer of purification processes to pilot-scale, GMP manufacturing, or external CDMOs
  • Experience with monoclonal antibodies, bispecifics, or other complex biologic modalities across multiple scales
  • Experience advancing platform purification strategies or implementing next-generation technologies to improve robustness, cost, and efficiency
  • Knowledge of statistical tools and data analysis approaches that support process understanding and scale-up decisions

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AbbVie filed SKYRIZI Crohn's subcutaneous induction with FDA on April 27, 2026.
  • AbbVie's June 22, 2026 Apogee acquisition adds asthma and dermatitis pipeline depth.
  • WCLC 2026 data showed 90% ABBV-1480 response rates, supporting Phase 3 advancement.

What critics are saying

  • Humira revenue plunged 47% in the U.S. during Q2 2026; biosimilars keep winning.
  • AbbVie still faces Humira antitrust and patent litigation, including Alvotech's active 2026 case.
  • ABBV-1480, Temab-A, and ABBV-706 remain unapproved; oncology failures would leave SKYRIZI-RINVOQ exposed.

What makes AbbVie unique

  • AbbVie's immunology franchise, SKYRIZI and RINVOQ, generated $8.79 billion in Q2 2026.
  • AbbVie converts 28.3% of revenue into free cash flow, funding buybacks and deals.
  • Botox, eye care, and neuroscience diversify earnings beyond immunology and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Yahoo Finance
Aug 21st, 2026
AbbVie stock moves independently from market with 0.22 correlation driven by immunology drugs

AbbVie stock shows a correlation of just 0.22 to the S&P 500 over five years, meaning most of its movements stem from company-specific factors rather than broader market trends. The pharmaceutical firm's immunology segment generated nearly $8.8 billion of its $17 billion in second-quarter 2026 revenue, led by SKYRIZI at $5.5 billion and RINVOQ at over $2.5 billion. These treatments for chronic diseases have prices negotiated with payers, not consumers. AbbVie has delivered an annualised return of 21.5% with 23.5% volatility over five years, compared to the S&P 500's 12.9% return at 17.2% volatility. The company converts 28.3% of revenue into free cash flow, nearly double the S&P 500 median of 14.5%.

Grafa
Aug 21st, 2026
AbbVie reports 90% response in lung cancer study.

AbbVie reports 90% response in lung cancer study. * AbbVie reported a 90% objective response rate for ABBV-1480 plus platinum chemotherapy in squamous advanced NSCLC at the selected 10 mg/kg dose. * The same dose produced a 75.9% response rate in non-squamous disease and was selected as the recommended Phase 3 dose. * AbbVie will also present data for Temab-A and ABBV-706 across NSCLC and small cell lung cancer at the 2026 World Conference on Lung Cancer. AbbVie (NYSE:ABBV) reported Phase 1b lung cancer data showing objective response rates of 90% in squamous and 75.9% in non-squamous advanced NSCLC with ABBV-1480 plus platinum chemotherapy. At the 10 mg/kg dose, 27 of 30 patients with squamous disease and 22 of 29 with non-squamous disease achieved objective responses, according to the company. AbbVie said the findings support further evaluation of ABBV-1480 in advanced NSCLC and selected the 10 mg/kg regimen as the recommended Phase 3 dose. The company will present additional clinical results for telisotuzumab adizutecan, or Temab-A, in first-line non-squamous and EGFR-mutated NSCLC at the 2026 World Conference on Lung Cancer. AbbVie will also report ABBV-706 data in relapsed or refractory small cell lung cancer, including new safety analyses covering 240 patients. The company's conference presentations include real-world evidence evaluating SEZ6 as a potential therapeutic target in small cell lung cancer. The updates form part of AbbVie's clinical development program across non-small cell and small cell lung cancers, with several investigational therapies being evaluated across different treatment settings. Frequently asked questions. ABBV signals

Yahoo Finance
Aug 19th, 2026
AbbVie stock eyes breakout as Skyrizi dosing decision could unlock $24.5B revenue growth

AbbVie stock has returned 24.5% over the past three months, trading near its 52-week high. The pharmaceutical company's growth hinges on a pending regulatory decision for SKYRIZI, an immunology treatment that generates nearly a third of guided revenue. SKYRIZI sold $5.5 billion in Q2 2026, up 24% operationally. AbbVie guides the drug to $21.7 billion for 2026 against total company revenue of approximately $67.6 billion. The company has raised its 2026 guidance twice by $600 million combined. A subcutaneous induction option for Crohn's disease awaits regulatory approval this fall. Management expects the new dosing method to meaningfully accelerate SKYRIZI sales, though the commercial impact won't materialise until early 2027 due to contract timelines. Clinical trial results showed endoscopic response and remission rates 25 points above placebo.

BBC
Aug 19th, 2026
UK's Smith+Nephew CFO John Rogers to step down for external role.

UK's Smith+Nephew CFO John Rogers to step down for external role. August 19, 2026 The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing International News via Reuters: Smith+Nephew said on Wednesday its finance chief John Rogers would step down at the end of September to take up an external position in the United States, ending his roughly two-and-a-half-year tenure with the medical products company. Here are some more details: - The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing. - Smith+Nephew said it had appointed Senior Vice President Finance and Group Controller Pierre Palassian as interim chief financial officer until a permanent replacement was appointed. - Palassian, who joined Smith+Nephew in 2017, previously held senior roles at AbbVie and Abbott Laboratories. - Rogers, who took up the CFO role in early 2024, had relocated to the United States in 2025 for operational efficiencies. - Shares in the FTSE 100 company have gained nearly 14% during Rogers' tenure as CFO. - Smith+Nephew said Rogers would receive no severance payment, and that his outstanding incentive and share awards would lapse on September 30 under leaver rules. Reporting by Neeshita Beura in Bengaluru; Editing by Subhranshu Sahu - Advertisement - August 19, 2026 - Advertisement -

Right Brain Bio, Inc.
Aug 19th, 2026
Tavapadon update.

Tavapadon update. Publication of a Phase 3 trial of the dopamine agonist tavapadon in mild PD shows that a new option will be available soon for people with PD. Tavapadon is a unique dopamine agonist, stimulating different dopamine receptors than the currently available agents. What I think of as first generation dopamine agonists - the ones that are available now (ropinirole, pramipexole and rotigotine) act via D2/D3 receptors to reduce the brake on movement. In contrast, what I call second generation drug acts via D1/D5 receptors to stimulate movement. The trials that I expect to yield FDA approval for tavapadon studied the effects of the drug compared to placebo. They showed benefit in people with mild PD [TEMPO-2] as well as those with more advanced disease as defined by motor complications [TEMPO-3]. It is a strong database. But ParkinsonsDisease don't have data to tell ParkinsonsDisease how to use 1st -gen vs. this 2nd gen dopamine agonist. Open questions include: · Does one more potent improve movement than the other? · Is one approach better tolerated with less side effects? · Are there situations where a person should switch from 1st -gen to this 2nd -gen therapy? · Could the two together or rotating between the two be the optimal approach? With such unanswered questions, how are ParkinsonsDisease to know how to use this new therapy? Conducting proper randomized clinical trials focused on each question is the only way. Trials comparing similar drugs: feasible and important. Abbvie is developing tavapadon after it was initially discovered by scientists at Pfizer. As a commercial entity, why would Abbvie conduct comparative studies that risk their drug being shown to be no better than a 1st-gen dopamine agonist, especially considering how cheap they are compared to a newly launched brand-name drug? Consider a couple of lessons. 1. Several companies selling the cholesterol-lowering statins were battling for market share (behind Lipitor). Bristol-Myers Squibb (BMS) sought to increase its share and launched a large-scale, multi-center, blinded, randomized clinical trial comparing its drug (Pravachol) to Lipitor. No one expected the two drugs to have equal cholesterol lowering effects, as Lipitor more potently lowered cholesterol. Instead, the trial focused on whether the clinical impact of any cholesterol lowering were similar or different. When I spoke with cardiologists about the trial, they seemed convinced that BMS knew something that made them confident enough to spend the millions of dollars the trial would cost - and so continued to write prescriptions for Pravachol. In the end, Pravachol was shown to be inferior (though still better than placebo). BMS did the right thing, though their gamble failed. 2. When the second beta-blocker was approved for treatment of heart failure, GlaxoSmithKline (GSK) was concerned that its drug (Coreg) could lose market share - including to a generic beta-blocker. It launched a major clinical trial comparing its brand name drug to the generic. Again, doctors talking about the trial seemed convinced that GSK knew something that made it risk its beta-blocker franchise. In the end, Coreg was proven to be clinical superior to the generic beta-blocker metoprolol (that was also effective). GSK's did the right thing and their gamble paid off. Abbvie could to the right thing, but If such a trial is not already being planned, I am not optimistic Abbvie is likely to conduct such a trial. A call to action. If Abbvie has not already factored in this gamble to their soon to be launched drug, I am not optimistic they are likely to announce such a trial. But there is a way. The NIH, the Michael J. Fox Foundation, the Parkinson's Foundation and Cure Parkinson's - amongst others - could band together and make it happen. This is not merely a scientific curiosity. This is a major clinical need. And if you agree, tell these Foundations that you want to know the answers to these questions. In case you missed it... About Jonathan Sackner-Bernstein, MD Dr. Sackner-Bernstein shares his pursuit of conquering Parkinson's, using expertise developed as Columbia University faculty, FDA senior official, DARPA insider and witness to the toll of PD. Dr. S-B's Linkedin page RightBrainBio, Inc. was incorporated in 2022 to develop tranformative therapies for people with Parkinson's. I post on LinkedIn to highlight this weekly newsletter and engage in conversations with others. There was an old video of Michael J. Fox being interviewed by Barbara Walters about his ability and inability to control his movement.